Related references
Note: Only part of the references are listed.Blocking inflammation to improve immunotherapy of advanced cancer
Antonio Maccio et al.
IMMUNOLOGY (2020)
Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
Jiahang Mo et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2020)
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Alexandre Reuben et al.
NATURE COMMUNICATIONS (2020)
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients
Lisa Derosa et al.
EUROPEAN UROLOGY (2020)
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
Delvys Rodriguez-Abreu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
Khalid AbdulJabbar et al.
NATURE MEDICINE (2020)
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Praveen Vikas et al.
FRONTIERS IN ONCOLOGY (2020)
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remon et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
Eliran Kadosh et al.
NATURE (2020)
Systemic and tumor associated IL-8 correlates with resistance to PD-L1 blockade
Kobe Yuen et al.
CANCER RESEARCH (2020)
A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies
Antonio Jimeno et al.
CANCER RESEARCH (2020)
Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
Johanna C. Bendell et al.
CANCER RESEARCH (2020)
Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC
Byoung Chul Cho et al.
CANCER RESEARCH (2020)
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Valsamo Anagnostou et al.
NATURE CANCER (2020)
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Michael Offin et al.
CLINICAL CANCER RESEARCH (2019)
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
Bo Gong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Takeshi Tanoue et al.
NATURE (2019)
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1
Alessandro Prestipino et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy
Gui-Zhen Wang et al.
NATURE COMMUNICATIONS (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Han Yao et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Association of BRCA1-and BRCA2-deficiency with mutation burden, expression of PD-L1/ PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
Wei Xiong Wen et al.
PLOS ONE (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Andrew Georgiadis et al.
CLINICAL CANCER RESEARCH (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
Carlo Genova et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Liquid biopsy tracking of lung tumor evolutions over time
Alessandro Russo et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott J. Antonia et al.
LANCET ONCOLOGY (2019)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer
Kroopa Joshi et al.
NATURE MEDICINE (2019)
Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
Sarah A. Best et al.
NATURE COMMUNICATIONS (2019)
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer
Terry L. Ng et al.
CANCER (2019)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (vol 28, pg 1368, 2017)
N. Chaput et al.
ANNALS OF ONCOLOGY (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Shunsuke Kitapma et al.
CANCER DISCOVERY (2019)
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
Xin Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
Michael Offin et al.
JCO PRECISION ONCOLOGY (2019)
Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer
Erin Bange et al.
JCO PRECISION ONCOLOGY (2019)
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
Giovanni Fuca et al.
ESMO OPEN (2019)
Beyond PD-1 Immunotherapy in Malignant Melanoma
Dominika Kwiatkowska et al.
DERMATOLOGY AND THERAPY (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions
Young Kwang Chae et al.
ONCOLOGIST (2018)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
L. Derosa et al.
ANNALS OF ONCOLOGY (2018)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
Keaping a lid on lung cancer: the Keap1-Nrf2 pathway
Sarah A. Best et al.
CELL CYCLE (2018)
MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.
Justin M. Balko et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report
Yuki Owada-Ozaki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
Elizabeth Dudnik et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The influence of diet on anti-cancer immune responsiveness
Laura Soldati et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
The gut microbiota influences anticancer immunosurveillance and general health
Bertrand Routy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing
Deng Pan et al.
SCIENCE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O'Donnell et al.
SEMINARS IN CANCER BIOLOGY (2018)
Impact of smoking on efficacy of PD-I/PD-LI inhibitors in non-small cell lung cancer patients: a meta-analysis
Bingjia Li et al.
ONCOTARGETS AND THERAPY (2018)
The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression
Smruti Pushalkar et al.
CANCER DISCOVERY (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Combining Immunotherapy and Radiotherapy for Cancer Treatment Current Challenges and Future Directions
Yifan Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Immunological Approaches Towards Cancer and Inflammation: A Cross Talk
Xinglong Qu et al.
FRONTIERS IN IMMUNOLOGY (2018)
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas A Phase 2 Clinical Trial
Maud Toulmonde et al.
JAMA ONCOLOGY (2018)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis
Chee Khoon Lee et al.
JAMA ONCOLOGY (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. K. Sabari et al.
ANNALS OF ONCOLOGY (2018)
Gut microbiota modulate T cell trafficking into human colorectal cancer
Eleonora Cremonesi et al.
CANCER RESEARCH (2018)
Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT
Jotham Suez et al.
CELL (2018)
Cigarette Smoke-Induced Emphysema Exhausts Early Cytotoxic CD8+ T Cell Responses against Nascent Lung Cancer Cells
Dimitra Kerdidani et al.
JOURNAL OF IMMUNOLOGY (2018)
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun et al.
LANCET ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
S. N. Gettinger et al.
NATURE COMMUNICATIONS (2018)
The clinical utility of tumor mutational burden in non-small cell lung cancer
Laurent Greillier et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis
Omar Abdel-Rahman
CLINICAL RESPIRATORY JOURNAL (2018)
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up (vol 28, pg 75, 2017)
H. Kadara et al.
ANNALS OF ONCOLOGY (2018)
Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L) 1 Blockade in Patients with NSCLC Despite High TMB
K. Arbour et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Methods of measurement for tumor mutational burden in tumor tissue
Barbara Melendez et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α
Yana G. Najjar et al.
CLINICAL CANCER RESEARCH (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Wenwen Du et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
Kentaro Inamura et al.
LUNG CANCER (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Is autoimmunity the Achilles' heel of cancer immunotherapy?
Carl H. June et al.
NATURE MEDICINE (2017)
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells
Giuliana P. Mognol et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
Susan Bullman et al.
SCIENCE (2017)
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Nicholas A. Manieri et al.
TRENDS IN IMMUNOLOGY (2017)
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Florie Bertrand et al.
NATURE COMMUNICATIONS (2017)
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Antje Sucker et al.
NATURE COMMUNICATIONS (2017)
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
Kazuyoshi Takeda et al.
NATURE COMMUNICATIONS (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Daniel Zingg et al.
CELL REPORTS (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Metabolic Hallmarks of Tumor and immune Cells in the Tumor Microenvironment
Kathrin Renner et al.
FRONTIERS IN IMMUNOLOGY (2017)
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
Siwen Hu-Lieskovan et al.
CANCER JOURNAL (2017)
Targeting immunosuppressive adenosine in cancer
D. Vijayan et al.
NATURE REVIEWS CANCER (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
Marco Donia et al.
CANCER RESEARCH (2017)
Epigenetic modulation in cancer immunotherapy
Stuart J. Gallagher et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism
Veronica De Rosa et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer
Valsamo Anagnostou et al.
CANCER RESEARCH (2017)
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
Carolina Pereira et al.
CLINICAL CANCER RESEARCH (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput et al.
ANNALS OF ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
T. Donnem et al.
ANNALS OF ONCOLOGY (2016)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
Nisha Nagarsheth et al.
CANCER RESEARCH (2016)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Tumor-associated macrophages in cancers
W. Hu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 alpha and STAT3
Jaemoon Koh et al.
ONCOIMMUNOLOGY (2016)
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
Jon Bjoern et al.
ONCOIMMUNOLOGY (2016)
Loss of PTEN promotes resistance to T cell-mediated immunotherapy
Weiyi Peng et al.
CANCER RESEARCH (2016)
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
Shohei Koyama et al.
CANCER RESEARCH (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Carlos Alfaro et al.
CLINICAL CANCER RESEARCH (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects
Romain Daillere et al.
IMMUNITY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
The role of neoantigens in response to immune checkpoint blockade
Nadeem Riaz et al.
INTERNATIONAL IMMUNOLOGY (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M. Mehnert et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer
Elisabeth Brambilla et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lung Cancer Subtypes Generate Unique Immune Responses
Stephanie E. Busch et al.
JOURNAL OF IMMUNOLOGY (2016)
CD8+ T Cells Play a Bystander Role in Mice Latently Infected with Herpes Simplex Virus 1
Kevin R. Mott et al.
JOURNAL OF VIROLOGY (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
Neoantigen landscape dynamics during human melanoma-T cell interactions
Els M. E. Verdegaal et al.
NATURE (2016)
The microbiome in early life: implications for health outcomes
Sabrina Tamburini et al.
NATURE MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma
Stefani Spranger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
The epigenetic landscape of T cell exhaustion
Debattama R. Sen et al.
SCIENCE (2016)
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
R. Dixon Dorand et al.
SCIENCE (2016)
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Kristen E. Pauken et al.
SCIENCE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer
Wen Feng et al.
ONCOTARGET (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Marios Giannakis et al.
CELL REPORTS (2016)
PD-1 Blockade Expands Intratumoral Memory T Cells
Antoni Ribas et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Macrophages and Therapeutic Resistance in Cancer
Brian Ruffell et al.
CANCER CELL (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
Claire Vanpouille-Box et al.
CANCER RESEARCH (2015)
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
Shin Foong Ngiow et al.
CANCER RESEARCH (2015)
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy
Pauline Maby et al.
CANCER RESEARCH (2015)
Antibiotics, Pediatric Dysbiosis, and Disease
Pajau Vangay et al.
CELL HOST & MICROBE (2015)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani et al.
CELL RESEARCH (2015)
Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis
Yiting Geng et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
CXCR4 Inhibition in Tumor Microenvironment Facilitates Anti-Programmed Death Receptor-1 Immunotherapy in Sorafenib-Treated Hepatocellular Carcinoma in Mice
Yunching Chen et al.
HEPATOLOGY (2015)
Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy
Chien-Chung Chang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
A. M. Martin et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
Daniela S. Thommen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition
Roch Houot et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
Michael Platten et al.
FRONTIERS IN IMMUNOLOGY (2015)
CXCL8-the first chemokine
Marco Baggiolini
FRONTIERS IN IMMUNOLOGY (2015)
CD73: A potential biomarker for anti-PD-1 therapy
Paul A Beavis et al.
OncoImmunology (2015)
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Aitziber Buque et al.
ONCOIMMUNOLOGY (2015)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt et al.
JAMA ONCOLOGY (2015)
Role of Local Radiation Therapy in Cancer Immunotherapy
Sandra Demaria et al.
JAMA ONCOLOGY (2015)
Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics
Cigall Kadoch et al.
SCIENCE ADVANCES (2015)
Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data
Patrick A. Ott et al.
FRONTIERS IN ONCOLOGY (2015)
Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
Geoffrey T. Gibney et al.
CLINICAL CANCER RESEARCH (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment
Stephen J. P. Blake et al.
PLOS ONE (2015)
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He et al.
SCIENTIFIC REPORTS (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
George C. Prendergast et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
Stephen Mok et al.
CANCER RESEARCH (2014)
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu et al.
CANCER RESEARCH (2014)
Gut Dysbiosis Promotes M2 Macrophage Polarization and Allergic Airway Inflammation via Fungi-Induced PGE2
Yun-Gi Kim et al.
CELL HOST & MICROBE (2014)
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Antje Sucker et al.
CLINICAL CANCER RESEARCH (2014)
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Stanleyson V. Hato et al.
CLINICAL CANCER RESEARCH (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
CTLA-4 Blockade Enhances Antitumor Immunity of Intratumoral Injection of Immature Dendritic Cells into Irradiated Tumor in a Mouse Colon Cancer Model
Cheol-Hun Son et al.
JOURNAL OF IMMUNOTHERAPY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Enhancing Chemotherapy Efficacy in Pten-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity
Alberto Toso et al.
CELL REPORTS (2014)
Single-Cell RNA Sequencing Reveals T Helper Cells Synthesizing Steroids De Novo to Contribute to Immune Homeostasis
Bidesh Mahata et al.
CELL REPORTS (2014)
CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Hye-Jung Kim et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRI lo/neg cells): the gateway to improved responses
Rebecca R. Laborde et al.
FRONTIERS IN IMMUNOLOGY (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Theerawut Chanmee et al.
CANCERS (2014)
Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity
Zong Sheng Guo et al.
FRONTIERS IN ONCOLOGY (2014)
Control of the immune response by pro-angiogenic factors
Thibault Voron et al.
FRONTIERS IN ONCOLOGY (2014)
Human memory T cells: generation, compartmentalization and homeostasis
Donna L. Farber et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Combinatorial TGF-β signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAFV600E-PTEN-/-transgenic model of melanoma
Brent Allen Hanks et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Macrophage Regulation of Tumor Responses to Anticancer Therapies
Michele De Palma et al.
CANCER CELL (2013)
Chemoimmunotherapy: reengineering tumor immunity
Gang Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Bertrand Allard et al.
CLINICAL CANCER RESEARCH (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Esra A. Akbay et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses
Li-Xin Wang et al.
PLOS ONE (2013)
Strength of PD-1 signaling differentially affects T-cell effector functions
Fang Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Noriho Iida et al.
SCIENCE (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Sophie Viaud et al.
SCIENCE (2013)
Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
Chao Ma et al.
CANCER DISCOVERY (2013)
Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants
Karen M. Kaluza et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma
Krithika N. Kodumudi et al.
JOURNAL OF IMMUNOLOGY (2012)
Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination
Ahmad A. Tarhini et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Jennifer Landsberg et al.
NATURE (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Mark S. Diamond et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Barbara Molon et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Density of Tumor-Infiltrating Lymphocytes Correlates with Disease Recurrence and Survival in Patients with Large Non-Small-Cell Lung Cancer Tumors
Arman Kilic et al.
JOURNAL OF SURGICAL RESEARCH (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights
Agnes E. Coutinho et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2011)
A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells
Chao Ma et al.
NATURE MEDICINE (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Gregory T. Motz et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
Vanessa Deschoolmeester et al.
BMC IMMUNOLOGY (2010)
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Subhra K. Biswas et al.
NATURE IMMUNOLOGY (2010)
Somatic Mutation Profiles of MSI and MSS Colorectal Cancer Identified by Whole Exome Next Generation Sequencing and Bioinformatics Analysis
Bernd Timmermann et al.
PLOS ONE (2010)
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota
June L. Round et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Combination of CTL-associated Antigen-4 Blockade and Depletion of CD25+ Regulatory T Cells Enhance Tumour Immunity of Dendritic Cell-based Vaccine in a Mouse Model of Colon Cancer
Asim Saha et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2010)
The polarization of immune cells in the tumour environment by TGFβ
Richard A. Flavell et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms
Enrico Ruffini et al.
ANNALS OF THORACIC SURGERY (2009)
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
Robbert G. van der Most et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
Dan D. Vo et al.
CANCER RESEARCH (2009)
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
Dong-Ming Kuang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Migration, maintenance and recall of memory T cells in peripheral tissues
David L. Woodland et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Regulatory T cells and immune tolerance
Shimon Sakaguchi et al.
CELL (2008)
Cancer as an overhealing wound:: an old hypothesis revisited
Matthias Schaefer et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Jedd D. Wolchok et al.
ONCOLOGIST (2008)
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Shawn D. Blackburn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Immunotherapy of autoimmunity and cancer: the penalty for success
Rachel R. Caspi
NATURE REVIEWS IMMUNOLOGY (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration
Paul Proost et al.
BLOOD (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice
Carsten T. Viehl et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
I Kryczek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells
DH Munn et al.
JOURNAL OF IMMUNOLOGY (2004)
Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes:: Role of cyclic adenosine 3',5'-monophosphate and phosphatases
H Zhang et al.
JOURNAL OF IMMUNOLOGY (2004)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
B7x: A widely expressed B7 family member that inhibits T cell activation
XX Zang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Regulation of dendritic cell migration to the draining lymph node:: Impact on T lymphocyte traffic and priming
A Martín-Fontecha et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-β-dependent mechanism
T Oida et al.
JOURNAL OF IMMUNOLOGY (2003)
Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo
A Sundstedt et al.
JOURNAL OF IMMUNOLOGY (2003)
The roles of IFNγ in protection against tumor development and cancer immunoediting
H Ikeda et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein
T Matsutake et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
